Viracta Therapeutics (VIRX) Reports Positive Data from the Phase 2 NAVAL-1 Trial

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. ACN
3. IBM
4. MU
5. NVDA
6. PRIM
7. META
8. SPY
9. SPCX
10. DPZ

Go back to Viracta Therapeutics (VIRX) Reports Positive Data from the Phase 2 NAVAL-1 Trial
(NASDAQ: VIRX) Delayed: 0.08 --0 (-0%)
Previous Close $0.08    52 Week High $ 
Open $0.08    52 Week Low $ 
Day High $0.08    P/E N/A 
Day Low $0.08    EPS $ 
Volume 1,449